Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Operations (2019 - 2025)

Historic Cash from Operations for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to -$31.2 million.

  • C4 Therapeutics' Cash from Operations fell 2931.26% to -$31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$109.8 million, marking a year-over-year decrease of 6808.84%. This contributed to the annual value of -$65.2 million for FY2024, which is 3901.33% up from last year.
  • Latest data reveals that C4 Therapeutics reported Cash from Operations of -$31.2 million as of Q3 2025, which was down 2931.26% from -$12.1 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Cash from Operations high stood at -$5.0 million for Q2 2024, and its period low was -$33.3 million during Q1 2025.
  • Moreover, its 5-year median value for Cash from Operations was -$24.1 million (2024), whereas its average is -$23.2 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 7381.69% in 2024, then plummeted by 14240.05% in 2025.
  • Quarter analysis of 5 years shows C4 Therapeutics' Cash from Operations stood at -$25.7 million in 2021, then decreased by 13.47% to -$29.1 million in 2022, then rose by 17.57% to -$24.0 million in 2023, then grew by 25.31% to -$17.9 million in 2024, then crashed by 74.03% to -$31.2 million in 2025.
  • Its last three reported values are -$31.2 million in Q3 2025, -$12.1 million for Q2 2025, and -$33.3 million during Q1 2025.